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a b s t r a c t
A number of hydroxamic acid derivatives which inhibit human histone deacetylases were investigated
for efﬁcacy against cultured bloodstream form Trypanosoma brucei. Three out of the four classes tested
displayed signiﬁcant activity. The majority of compounds blocked parasite growth in the submicromolar
range. The most potent was a member of the sulphonepiperazine series with an IC50 of 34 nM. These
results identify lead compounds with potential for the development of a novel class of trypanocidal agent.
 2012 Elsevier Ltd. All rights reserved.
Tsetse ﬂy transmitted protozoa of the Trypanosoma brucei spe-
cies complex are the causative agents of human African trypanoso-
miasis (HAT). There are currently around 30,000 HAT cases
annually, although during epidemics, such as in the late 1990s, this
level can increase by more than 10-fold.1–3 In domesticated
animals these parasites also cause nagana, a disease which has a
major impact on agricultural output throughout sub-Saharan
Africa. T. brucei is an extracellular parasite that avoids immune
destruction by a complex process of antigenic variation. This is
mediated by periodic switching of the single variant surface glyco-
protein (VSG) that covers the parasite cell surface to another anti-
genically distinct type, encoded by the large repertoire of VSG
genes.4 As a consequence, vaccines are not a realistic option. Drug
development is therefore of major importance, and is a WHO pri-
ority. Existing therapies for HAT are unsatisfactory for reasons that
include severe toxic side effects, increasing resistance, the need for
hospitalisation during administration and cost.5,6 In the absence of
treatment, late stage disease is almost invariably fatal.5
Histone modiﬁcations play a central role in transcription, chro-
matin assembly, replication, DNA repair and other regulatory pro-
cesses central to chromosome biology. For example, coupled
acetylation/deacetylation reactions, carried out by histone
acetyltransferases and histone deacetylases (HDAC), respectively,
are widespread within eukaryotes and act as regulators of numer-
ous cellular events.7,8 Aberrant HDAC activity has been associated
with a number of different diseases and enzyme inhibitors have
broad therapeutic potential.9,10 This is particularly the case with
cancer, where anti-proliferative effects can result from induction
of cell cycle arrest and apoptosis.11 In T. brucei, there are four puta-
tive non-sirtuin HDAC isoforms, of which two (DAC1 and DAC3)
are essential in bloodstream form parasites12 and play distinct
roles in the telomeric silencing of non-expressed VSG genes.13 Evi-
dence also suggests a role for histone acetylation in epigenetic reg-
ulation of RNA polymerase II polycistronic transcription.14 Previous
studies have demonstrated that inhibitors of HDAC can have signif-
icant anti-malarial and anti-leishmanial properties,15–17 in addi-
tion to activity against a range of other parasites. For instance,
the HDAC inhibitor Trichostatin A suppresses growth of blood-
stream form T. brucei,18 and is an inhibitor of DAC1 and DAC3 activ-
ity.13 Here, we report the efﬁcient growth inhibition of cultured
bloodstream form T. brucei using a series of inhibitors of human
HDACs.
A representative set of HDAC inhibitors was selected by screen-
ing our large compound library. These compounds were originally
prepared as part of a programme to identify HDAC inhibitors with
anti-cancer properties. This resulted in the discovery of the drug
candidate Belinostat, currently in phase III clinical trials. The se-
lected compounds were all hydroxamic acid derivatives, a common
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Scheme 1. Preparation of hydroxamic acids with a sulphoneamide or sulphonepiperazine linker.
Table 1
Prepared HDAC inhibitors and biological activity23,24,29,30
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Comp. 1-8, 10-15, 17-19 Comp, 9, 16, 20 Comp. 21-26
Compound R1 R2 R3 Trypanosoma brucei (BSF) HDAC (FDL_HELA)
IC50 ± SD (lM) IC90 ± SD (lM) IC50 ± SD (lM)
1 N
N
N
N
0.034 ± 0.002 0.066 ± 0.004 0.084 ± 0.053
2 N
N
Cl
0.064 ± 0.005 0.130 ± 0.005 0.149 ± 0.006
3
N
N
N
0.086 ± 0.009 0.201 ± 0.005 0.123 ± 0.076
4 N
N
Cl 0.123 ± 0.006 0.169 ± 0.008 0.187 ± 0.082
5
O
F3C
H
N
0.137 ± 0.007 0.22 ± 0.007 nd
6 N
NF
0.141 ± 0.009 0.224 ± 0.014 0.191 ± 0.036
7 N
NCl
0.154 ± 0.013 0.281 ± 0.019 0.068 ± 0.036
8
O
F2HC
H
N
0.154 ± 0.013 0.306 ± 0.061 0.01 ± 0.002
9
N
O
0.155 ± 0.018 0.310 ± 0.040 0.028 ± 0.004
10 N
N
O
0.156 ± 0.003 0.224 ± 0.003 0.212 ± 0.112
11 0.167 ± 0.012 0.228 ± 0.002 0.132 ± 0.103
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structural feature of HDAC inhibitors due to the high afﬁnity of this
group for the Zn(II) ion in the metalloenzyme. Four hydroxamic
acid compound subclasses, belonging to separate patent series,19–
22 the sulphoneamides, sulphonepiperazines, long chain amides
and a heterocyclic series, were chosen for screening against
trypanosomes.
Compounds 1–8, 10–15 and 17–19,which are hydroxamic acids
with a sulphoneamide or sulphonepiperazine linker in the mole-
cule, were prepared according to previously described proce-
dures.19,20 Brieﬂy, they were synthesized from the corresponding
sulphonyl chloride and amide or piperazine, followed by the trans-
formation of the methyl ester to the desired hydroxamic acid
(Scheme 1, Table 1). Hydroxamic acid derivatives with a long chain
amide linker, compounds 21–26, were synthesized by amide cou-
pling between the methyl 6-aminohexanoate and the respective
acid, followed by transformation of the ester to the corresponding
Table 1 (continued)
Compound R1 R2 R3 Trypanosoma brucei (BSF) HDAC (FDL_HELA)
IC50 ± SD (lM) IC90 ± SD (lM) IC50 ± SD (lM)
N
N
12 N
NO
0.198 ± 0.005 0.265 ± 0.005 0.022 ± 0.002
13
H
NO
0.198 ± 0.021 0.333 ± 0.028 0.022 ± 0.002
14
N
N
O
O
0.261 ± 0.038 0.485 ± 0.043 0.269 ± 0.087
15
H
NF
0.343 ± 0.017 0.710 ± 0.017 0.02 ± 0.004
16
N
0.353 ± 0.016 0.648 ± 0.020 0.022
17
H
N
Cl
0.368 ± 0.023 0.651 ± 0.083 0.042 ± 0.011
18
H
N
O
0.606 ± 0.081 0.956 ± 0.035 0.013 ± 0.005
19
H
N
O
O
0.927 ± 0.057 2.15 ± 0.14 0.023 ± 0.005
20
O
N
1.54 ± 0.06 2.18 ± 0.18 0.048 ± 0.028
21 O
O
N
H
O
>10 0.029 ± 0.016
22 N
H
O
>10 0.02 ± 0.002
23 N
H
O
>10 0.026 ± 0.036
24 N
O
>10 nd
25 >10 0.018 ± 0.006
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hydroxamic acid (Scheme 2, Table 1).21,23 Finally, the heterocyclic
hydroxamic acids 9, 16, 20, were similarly prepared using pub-
lished procedures.22
The compounds from the different structural subclasses were
all active as HDAC inhibitors, measured in an assay of enzymes
in HeLa cell lysates.23,24 HeLa cells express multiple HDACs, includ-
ing HDAC 1, 2, 3, 4, and 8.25–27 The compounds showed broad
selectivity, with submicromolar activities (Table 1). To further
characterise the compounds with respect to HDAC selectivity, we
determined their inhibitory properties against recombinant ex-
pressed human HDACs (rhHDAC 1–4, 6–9).28 These assays showed
that the compounds had a broad and potent inhibitory activity to-
wards these enzymes which belong to the different HDAC sub-
classes (class I, HDAC 1, 2, 3, 8; class IIA, HDAC 4, 7, 9; class IIB,
HDAC 6) (Table 2).
When we investigated the potency of the inhibitors against
cultured bloodstream form Trypanosoma brucei (strain 427),29,30
we found that three out of the four subclasses had signiﬁcant
activity, with growth inhibition occurring in the submicromolar
range (Table 1, Fig. 1). The most active compounds were the sul-
phonepiperazines, particularly those with an aromatic substitu-
tion attached to the piperazine moiety. Compounds 1–4, 6, 7,
and 10–12 are examples of the closely related analogues which
exhibit similar levels of potent activity (IC50 0.034–0.20 lM, Table
1). Treatment of parasites with micromolar levels of these inhib-
itors could result in cell death within 4 h (Fig. 1). In this sul-
phonepiperazine series, the close SAR suggests that further
modiﬁcation of the scaffold could enhance the trypanocidal prop-
erties. The sulphoneamide analogues 5, 8, 15, 17–19 also dis-
played signiﬁcant potency against bloodstream form parasites
(IC50 0.14–0.93 lM, Table 1), which showed a clear SAR. Interest-
ingly, although analogues from both classes inhibited HeLa cell
HDACs at a range of submicromolar concentrations (IC50 0.010–
0.19 lM), there was no obvious correlation with the pattern of
activity observed against trypanosomes.
The heterocyclic compounds 9 and 16, which are close quino-
line analogues, displayed similar trypanocidal properties (Table
1). However compound 20, a benzoxazole, thus structurally dis-
tinct from the other two heterocycles was 5- to 10-fold less active.
The amide series, which contains a C5 carbon linker (compounds
21–26), did not show activity against T. brucei (up to 10 lM, Table
1), despite being very potent inhibitors of HeLa cell HDACs. Com-
parison of the trypanosome inhibitory properties of compounds
1–20, which have an aromatic group attached close to the hydroxa-
mic acid, with those of the inactive amide series (compounds 21–
26), suggests that structural differences between human and T.
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Scheme 2. Preparation of hydroxamic acids with a long chain amide linker.
Table 2
Inhibition of rhHDAC isoformsa
Compound/rhHDAC ED50(nM ± SD)
1 2 3 4 6 7 8 9
3 nd 55 ± 6 2.8 ± 0.4 nd 179 ± 115 100 ± 97 581 ± 334 86 ± 61
10 76 ± 6 36 ± 0.7 295 ± 290 870 107 ± 13 nd 955 ± 166 1179
12 53 ± 3 310 ± 28 96 ± 46 nd 305 ± 19 nd 328 ± 193 145 ± 151
15 44 ± 0.1 221 ± 141 89 ± 32 65 ± 20 35 ± 16 216 ± 133 211 ± 42 109 ± 56
18 19 ± 1 105 ± 64 23 ± 2 33 ± 1 36 ± 3 42 ± 22 167 ± 72 26 ± 3
20 134 ± 6 554 ± 44 97 ± 0.6 373 ± 73 68 ± 13 286 ± 8 573 ± 30 278 ± 65
25 7.3 ± 1.7 7.2 ± 1.0 9.2 ± 1.9 6.6 ± 0.7 14 ± 9 8.4 ± 2.0 3033 ± 226 7.4 ± 4.3
nd = not determined.
a Each compound was assayed in triplicate per plate. EC50 values were determined from the average of a minimum of two plates. Results are means ± SD.
Figure 1. Bloodstream form T. brucei bloodstream treated with compound 1 (2 lg/ml). At the time points indicated, parasites were ﬁxed methanol, stained with Giemsa and
visualised using a Leica DMRB microscope.
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brucei target enzymes may inﬂuence the efﬁciency of inhibitor
binding. Importantly, the selectivity implies that the trypanocidal
activity results from speciﬁc interaction(s), rather than from gen-
eral metal ion chelating properties. Therefore, the disparity in
activity proﬁles of these compounds against human and parasite
cells could be due, at least in part, to their differential abilities to
inhibit the corresponding HDACs, or other metalloproteins. Inter-
estingly, the two essential T. brucei HDACs (DAC 1 and 3) are diver-
gent, relative to their mammalian counterparts, as are their histone
substrates. The major differences lie in the amino and carboxyl
extensions beyond the more conserved catalytic core. There is also
a large (174 amino acid) insert within the core of the class II en-
zyme, DAC3.12 The structures of these enzymes have yet to be
determined. However, HDAC inhibitors typically function through
chelation of the active site zinc ion, and the DAC3 insert, as well
as the other differences, may have an impact on access to the active
site pocket for both substrates and inhibitors. It is notable here that
highly speciﬁc selective inhibitors have been identiﬁed for human
HDACs31,32 and the differences between the human and T. brucei
enzymes might also be exploited for the development of trypano-
some selective inhibitors.
In conclusion, by screening a library of compounds produced for
anti-cancer studies, we have identiﬁed leads with potential for
treating African trypanosomiasis. These data provide a platform
for the deﬁnitive identiﬁcation of the target enzyme(s) within
the parasite and the informed design of more potent compounds
with optimised pharmacokinetic properties.
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